Ruti Aga Banned Six Years: How a Forged Prescription Turned Two Years into Six

The first thing visible in the Athletics Integrity Unit (AIU) statement is not emotion but arithmetic. Two years for presence. Four years for tampering. Six in total. And the count runs from 10 September — the exact date of the provisional suspension. Anyone reading the backdated start as a concession is misreading it: provisional suspension time is credited against the ban, so the athlete gains nothing in real terms. What has gone is the 2028 Olympic cycle. Subtract six years from thirty-two and thirty-eight remains — and no one selects a thirty-eight-year-old marathoner carrying a doping file in a country whose women's marathon depth is the deepest on earth. She won a half marathon in China in March. That race yields no mark, no split, no field detail in the source, so any performance claim would be fabrication. What is on the record is not the race; it is the document. A ledger does not keep highlight reels, it keeps dates.

A technical correction must come first, because the media report has the case pointing the wrong way. It calls methylprednisolone a "prohibited steroid" and performance-enhancing per WADA. That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). The distinction decides the entire legal centre of the case. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out-of-competition is entirely lawful; a violation arises only if residues are present in-competition. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier is still caught. The real question was never whether the drug was given; it was when, and by what route.

The athlete profile clarifies one more thing. Aga is thirty-two — late peak shading into decline. The source gives no personal best, but external records place her peak at 2026–2026 with no improvement after. Three World Marathon Majors runner-up finishes; the 2026 Tokyo Marathon title. None of it is disturbed unless the March race itself is established as the anchor. That is the most important detail the report quietly drops: prior-date results are not automatically annulled. The 2026 Berlin second place and the 2026 Tokyo gold stand on the record. A genuinely elite career and a banned period will both be filed under the same name. That is what an honest ledger does — it does not erase one to decorate the other.

Now the real story. The prescription. According to the AIU, Aga submitted a prescription to justify treatment of a knee injury. The investigation found her "doctor" was not a doctor at all — a family member with no medical registration who claimed to have used "an old prescription pad from a former workplace." When the clinic was asked, it flatly disowned the document. Three independent verification failures sit here together: no clinic in existence, no medical registration, and a disowned prescription pad. Not one fact stands under the document.

The root of the whole affair is the knee injury, and that is what troubles me most. Intra-articular or peri-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners. Something in March demanded treatment; otherwise why manufacture a slip at all? And here is the paradox: the rationale is medical, but the entire defence is paper. An athlete with real records fights with real records. A forged prescription is evidence that no real prescription existed — and that knee is a governance problem, not a treatment problem.

Where that gap comes from is buried in the set-up. East African road racing runs on altitude clubs, agents and informal medical networks. A runner who does three or four Majors a year plus Asian label races has neither a permanent team physician nor TUE infrastructure. The cheapest, most available tool for keeping a battered knee painless is a steroid. The ban does not look beneath that medical vacuum; it punishes the window where the sample was taken.

Now the angle almost nobody has taken. The AIU arithmetic says two years for presence, four for tampering. That is standard architecture, not an exception. Two years means the panel found the substance proven but no aggravated intent — that is, the no-significant-fault mitigation did not apply. That is where the strategy cracked. Because S9 is prohibited in-competition only, Aga had a legitimate defence pathway: timing, route and medical necessity. With a proper TUE and correct washout timing, the case might never have existed. By fabricating the prescription, Aga destroyed her one workable defence — that is the difference between the report and reality. The report frames it as a "steroid" case when it is a case about a substance with no proven endurance benefit. Six years — for a glucocorticoid that does not make a runner faster — is a sentence for document fraud, not for performance enhancement.

That is why this case turns the Asian label-race circuit into a new scrutiny zone. Chinese half marathons have been the most lucrative low-risk income tier for East African runners between Majors. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races. From Atlanta onward, the sample sheets and verification letters I have handled teach one thing: the enforcement frontier has moved from "detection" to "document verification." This case is not an outlier; it belongs to a recognizable family where a substance violation is compounded by a fabricated explanation.

There is a second lesson for those outside the circuit. The knee appearing and a slip being manufactured immediately is a habit, not an incident. It suggests a long-running injury suppressed informally again and again. And where such a habit forms, management or an agent is rarely absent — yet the AIU statement names only the family member. Where the investigation stopped, the source does not say. It is an incomplete file, and incomplete files breed the next case.

One thing reminds me of an old habit. In 2026, after the Delhi bans, I pulled my own 2026 notebooks and found a coach quoted saying "supplements are handled by the team" — and no follow-up question from me. Since then every women's athlete profile I keep carries a testing and supplement history, sourced to lab dates rather than quotes. So this forged prescription does not surprise me; it warns me. The paper trail starts before the medal and outlasts the roar.

One asterisk must be flagged, and I will not bury it at the end. The source does not state the year of the March race or the ban start year; the phrasing implies both are the current year, but that is inference, not fact. Nor does it explicitly state that the March result and prize money are void, though standard AIU practice annuls the competition where the sample was collected. The rest must wait on the record.

What comes next? The appeal window stays open, but document-based findings are hard to overturn. The real question is whether the next time an East African runner is injected in the knee, there will be a real prescription, a real clinic and a filed TUE — or another old prescription pad. The clock never lies; neither does a document. The difference is that the clock testifies every time, and the prescription only when someone asks.